Validation of the Cough Quality-of-Life Questionnaire in Patients With Idiopathic Pulmonary Fibrosis

Lechtzin, Noah; Hilliard, Marisa E.; Horton, Maureen R.

doi:10.1378/chest.12-2870

Cited by 58 publications

(43 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical courses of the IPF patients in this study widely varied; therefore, disease activity should be carefully monitored (32). From a clinical point of view, cough has been proposed as a prognostic indicator of IPF (33,34). Never-smoking IPF patients showed poor survival after adjustment of baseline CPI.…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status

Kishaba¹,

Nagano²,

Nei³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonias (IIPs) of unknown etiology that often affects male, elderly smokers. However, it is sometimes observed in never smokers. This study aimed to clarify the clinical characteristics of IPF in never-smoking patients compared with those in smoking patients. Methods:We retrospectively reviewed medical records, pulmonary function tests, and chest highresolution computed tomography (HRCT) scan of never-smoking and smoking IPF patients from July 1, 2008 to June 30, 2013 at our hospital.Results: We identified 32 never-smoking IPF patients and 66 smoking IPF patients. Never-smoking IPF patients developed more acute exacerbation (AE) than smoking IPF patients (50% vs. 18.2%, P<0.0001). Conclusions:In conclusion, never-smoking IPF patients developed AE more often and showed poor prognosis compared with smoking IPF patients. The 1-year mMRC breathlessness scale was an important predictor of mortality at our hospital.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status

Kishaba¹,

Nagano²,

Nei³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…Using the Cough Quality-of-Life Questionnaire [66], they showed that thalidomide significantly improved cough in IPF patients. However, adverse events (mainly constipation, dizziness and malaise) occurred with high prevalence in patients receiving thalidomide.…”

Section: Coughmentioning

confidence: 99%

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

Ferrara

Luppi²,

Birring

et al. 2018

Eur Respir Rev

View full text Add to dashboard Cite

Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach aimed to improve and optimise quality of life (QoL) in patients affected by progressive diseases. In this sense, it excludes and might be complementary to other interventions directly targeting the disease. BSC improves survival in patients with different types of cancer. Patients with idiopathic pulmonary fibrosis (IPF) experience a vast range of symptoms during the natural history of the disease and might have a beneficial effect of BSC interventions. This review highlights the current evidence on interventions targeting QoL and gaps for the clinical assessment of BSC in the treatment of IPF patients. Very few interventions to improve QoL or improve symptom control are currently supported by well-designed studies. Sound methodology is paramount in evaluating BSC in IPF, as well as the use of validated tools to measure QoL and symptom control in this specific group of patients.

show abstract

“…Nine studies 61,[109][110][111][112][113][114][115][116] assessed HRQoL using the SF-36, seven used the SGRQ, 55,73,[117][118][119][120][121][122] five studies used both the SF-36 and SGRQ [123][124][125][126][127] and two studies used the SF-36, the SGRQ and the EQ-5D 68,72 (Table 65). Two studies used the EQ-5D.…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

“…55,68,72,73,[117][118][119][120][121][122][123][124][125][126][127] The SGRQ is a disease-specific measure which aims to assess the impact of obstructive airways disease on overall health, daily life and perceived well-being. 135 It comprises 50 items within two parts, which cover three components of symptoms, activity and impact.…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Loveman

Copley

Colquitt

et al. 2015

Health Technology Assessment

View full text Add to dashboard Cite

BackgroundIdiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease that generally affects people over 60 years old. The main symptoms are shortness of breath and cough, and as the disease progresses there is a considerable impact on day-to-day life. Few treatments are currently available.ObjectivesTo conduct a systematic review of clinical effectiveness and an analysis of cost-effectiveness of treatments for IPF based on an economic model informed by systematic reviews of cost-effectiveness and quality of life.Data sourcesEleven electronic bibliographic databases, including MEDLINE, EMBASE, Web of Science, and The Cochrane Library and the Centre for Reviews and Dissemination databases, were searched from database inception to July 2013. Reference lists of relevant publications were also checked and experts consulted.MethodsTwo reviewers independently screened references for the systematic reviews, extracted and checked data from the included studies and appraised their risk of bias. An advisory group was consulted about the choice of interventions until consensus was reached about eligibility. A narrative review with meta-analysis was undertaken, and a network meta-analysis (NMA) was performed. A decision-analytic Markov model was developed to estimate cost-effectiveness of pharmacological treatments for IPF. Parameter values were obtained from NMA and systematic reviews. Univariate and probabilistic sensitivity analyses were undertaken. The model perspective is NHS and Personal Social Services, and discount rate is 3.5% for costs and health benefits.ResultsFourteen studies were included in the review of clinical effectiveness, of which one evaluated azathioprine, threeN-acetylcysteine (NAC) (alone or in combination), four pirfenidone, one BIBF 1120, one sildenafil, one thalidomide, two pulmonary rehabilitation, and one a disease management programme. Study quality was generally good, with a low risk of bias. The current evidence suggests that some treatments appear to be clinically effective. The model base-case results show increased survival for five pharmacological treatments, compared with best supportive care, at increased cost. General recommendations cannot be made of their cost-effectiveness owing to limitations in the evidence base.LimitationsFew direct comparisons of treatments were identified. An indirect comparison through a NMA was performed; however, caution is recommended in the interpretation of these results. In relation to the economic model, there is an assumption that pharmacological treatments have a constant effect on the relative rate of per cent predicted forced vital capacity decline.ConclusionsFew interventions have any statistically significant effect on IPF and a lack of studies on palliative care approaches was identified. Research is required into the effects of symptom control interventions, in particular pulmonary rehabilitation and thalidomide. Other research priorities include a well-conducted randomised controlled trial on inhaled NAC therapy and an updated evidence synthesis once the results of ongoing studies are reported.Study registrationThis study is registered as PROSPERO CRD42012002116.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract

Validation of the Cough Quality-of-Life Questionnaire in Patients With Idiopathic Pulmonary Fibrosis

Cited by 58 publications

References 22 publications

Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status

Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Contact Info

Product

Resources

About